SOURCE-LINKED STUDY SUMMARY
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.
Abstract summarizedQuality not appraised
- What was studied
- Assessed whether oral nicotinamide riboside was safe, raised brain NAD and altered cerebral metabolism in newly diagnosed Parkinson’s disease.
- Who / model studied
- Thirty newly diagnosed, treatment-naive patients with Parkinson’s disease entered the double-blind phase I trial.
- Studied dose & schedule
- Participants received oral NR at 1,000 mg or placebo for 30 days.
- What the study found
- NR was well tolerated and produced a significant but variable brain-NAD increase. Responders showed altered cerebral metabolism associated with mild clinical improvement.
- Limitations & context
- This phase I trial was small and lasted 30 days. Clinical improvement was mild and occurred among brain-NAD responders, so therapeutic efficacy remains unproven.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.cmet.2022.02.001